menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Porton Advanced partners with Eureka Therapeutics for TCell Therapy

    PR NEWSWIRE

    Eureka Announces UCSF Benioff Children’s Hospitals for ARYA-2 Clinical Trial

    BUSINESSWIRE

    Eureka Advances PII for Treatment of Liver Cancer Using GPC3-Targeting

    BUSINESSWIRE

    Eureka Awarded $10.6 Million CIRM Grant to Support Clinical Trial of ARTEMIS

    BUSINESSWIRE

    Eureka Licenses Antibody Targeting Mesothelin from National Cancer Institute

    BUSINESSWIRE

    Eureka Announces License with the NCI for GPC2 ARTEMIS T Cell Therapy

    BUSINESSWIRE

    Eureka Receives Orphan Drug Designations for Treatment of Hepatoblastoma

    BUSINESSWIRE

    SPAC on track: Estrella Biopharma signs deal with TradeUP

    FIERCEBIOTECH

    Eureka Announces New England Journal of Medicine Publication of Study of GPRC5D

    BUSINESSWIRE

    Eureka Announces Publication of Crystal Structure of TCR Mimic

    BUSINESSWIRE

    Eureka Tx Announces Publication of Study Demonstrating Broad Anti-Tumor Activity

    BUSINESSWIRE

    Eureka Tx, City of Hope Treat First Patient with GPC3 Targeting ARTEMIS T Cells

    BUSINESSWIRE

    Eureka Therapeutics to Present at the 18th Annual PEGS Boston Conference & Expo

    BUSINESSWIRE

    Eureka Tx Receives ODD for Hepatocellular Carcinoma With ARTEMIS T Cells

    BUSINESSWIRE

    Eureka Initiates Phase I/II ARYA-2 Trial of ET140203 ARTEMIS T Cells

    BUSINESSWIRE

    Imugene, Eureka Collaborate to Advance Oncolytic Virus and T-Cell Therapy

    BUSINESSWIRE

    Chutes & Ladders—Pfizer`s development leader is retiring in early 2022

    FIERCEBIOTECH

    Eureka Announces Initiation of Phase I/II ARYA-3 Clinical Trial of ARTEMIS®

    BUSINESSWIRE

    ACB hires Liu from Eureka Therapeutics to lead push into clinic

    FIERCEBIOTECH

    Eureka Therapeutics Announces Successful Preclinical Results of InvisiMask™

    BUSINESSWIRE

    Eureka Therapeutics Announces Successful Preclinical Results of InvisiMask™

    BUSINESSWIRE

    COVID-19 nasal spray from Eureka protects mice against infection

    FIERCEBIOTECH

    Eureka Therapeutics Appoints Nobel Laureate Randy Schekman, Ph.D

    BIOSPACE

    Eureka Announces Initiation of ARYA-1 Clinical Trial to Evaluate ET140203

    BUSINESSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.